Welcome to our dedicated page for IO Biotech SEC filings (Ticker: IOBTQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IO Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IO Biotech's regulatory disclosures and financial reporting.
IO Biotech, Inc. notifies that its Common Stock has been removed from listing and/or registration on the Nasdaq Stock Market LLC under Form 25.
The filing states Nasdaq followed 17 CFR 240.12d2-2 procedures and that the issuer complied with Exchange rules governing a voluntary withdrawal.
Lundbeckfond Invest A/S, a major shareholder of IO Biotech, Inc., filed Amendment No. 2 to its Schedule 13D reporting its position and recent events at the company. Lundbeckfond Invest reports beneficial ownership of 21,851,920 shares of IO Biotech common stock, representing 27.4% of the class, based on 71,948,842 shares outstanding as of November 10, 2025. On March 31, 2026, IO Biotech ceased operations and filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware, and its assets will be liquidated with claims paid according to statutory priorities. On the same date, all members of IO Biotech’s board of directors, including Christian Elling, resigned from the board and its committees.
IO Biotech, Inc. reports that Reporting Person Jorey Chernett no longer beneficially owns any shares of common stock as of the close of business on May 19, 2026. The filing is an Amendment No. 2 to a Schedule 13G/A reflecting an exit filing.
The cover information lists the class as Common Stock, $0.001 par value (CUSIP 449778109). The signature block is dated 05/20/2026.
IO Biotech, Inc. amended a Schedule 13G to report that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen beneficially own 0% of the company's common stock as of the close of business on March 31, 2026. The filing lists the reporting persons and their Delaware/U.S. status.